In 299 adults with complicated UTI from ESBL-producing Enterobacterales improving after 3–7 days of IV antibiotics, switching to oral fosfomycin was noninferior to continued IV therapy for clinical cure (92.8% vs 95.2%; risk difference −2.47%), with similar safety.
RCTn = 299
Seo et al. Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial